Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms.
作者信息
Loscocco Giuseppe Gaetano, Mora Barbara, Gangat Naseema
机构信息
Department of Experimental and Clinical Medicine, CRIMM, Canter of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Division of Hematology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
出版信息
Front Oncol. 2024 Jul 16;14:1454837. doi: 10.3389/fonc.2024.1454837. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms.社论：骨髓增殖性肿瘤中突变图谱的生物学和临床意义
Front Oncol. 2024 Jul 16;14:1454837. doi: 10.3389/fonc.2024.1454837. eCollection 2024.
2
JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.哥伦比亚BCR-ABL阴性骨髓增殖性肿瘤患者的JAK2、CALR和MPL突变谱
Colomb Med (Cali). 2023 Sep 30;54(3):e2035353. doi: 10.25100/cm.v54i3.5353. eCollection 2023 Jul-Sep.
3
MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.MPL 过表达诱导高水平的突变-CALR/MPL 复合物：CALR 突变的骨髓增殖性肿瘤中鲁索替尼耐药的新机制。
Int J Hematol. 2021 Oct;114(4):424-440. doi: 10.1007/s12185-021-03180-0. Epub 2021 Jun 24.
4
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.综合基因组分析阐明了 JAK-STAT 通路激活在骨髓增殖性肿瘤发病机制中的核心作用。
Blood. 2014 May 29;123(22):e123-33. doi: 10.1182/blood-2014-02-554634. Epub 2014 Apr 16.
5
JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.中国汉族原发性血小板增多症患者的JAK2、MPL和CALR基因突变
Hematology. 2017 Apr;22(3):145-148. doi: 10.1080/10245332.2016.1252003. Epub 2016 Nov 22.
6
Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.CALR、MPL 和 c-kit 基因突变在 JAK2 V617F 阴性骨髓增殖性肿瘤泰国患者中的研究。
Asian Pac J Cancer Prev. 2022 May 1;23(5):1671-1678. doi: 10.31557/APJCP.2022.23.5.1671.
7
[Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].208例BCR/ABL1阴性慢性骨髓增殖性疾病中JAK2、CALR、MPL基因突变的检测及诊断价值
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Aug;26(4):1122-1128. doi: 10.7534/j.issn.1009-2137.2018.04.030.
8
[Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].[单中心1648例费城染色体阴性骨髓增殖性肿瘤患者中JAK2、CALR和MPL基因突变的临床意义]
Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):295-300. doi: 10.3760/cma.j.issn.0253-2727.2017.04.007.
9
Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.印度BCR-ABL1阴性骨髓增殖性肿瘤的分子遗传学
Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):209-213. doi: 10.4103/IJPM.IJPM_223_17.
10
The Impact of JAK2 V617F, CALR, and MPL Mutations as Molecular Diagnostic Markers of Myeloproliferative Neoplasms in Kurdish Patients. A Single-center Experience.JAK2 V617F、CALR 和 MPL 突变作为库尔德患者骨髓增殖性肿瘤分子诊断标志物的影响。单中心经验。
Cell Mol Biol (Noisy-le-grand). 2022 Aug 31;68(8):202-209. doi: 10.14715/cmb/2022.68.8.34.
引用本文的文献
1
Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults.儿童、青少年和青年骨髓增殖性肿瘤的生物标志物
Cancers (Basel). 2024 Dec 8;16(23):4114. doi: 10.3390/cancers16234114.
本文引用的文献
1
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.RR6模型用于预测芦可替尼治疗6个月后生存率的验证及分子整合
Haematologica. 2024 Oct 1;109(10):3398-3403. doi: 10.3324/haematol.2024.285098.
2
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.在JAK2-V617F阳性骨髓增殖性肿瘤中，Dnmt3a的缺失增加了自我更新能力以及对聚乙二醇干扰素-α的抗性。
Blood. 2024 Jun 13;143(24):2490-2503. doi: 10.1182/blood.2023020270.
3
CALR mutation burden in essential thrombocythemia and disease outcome.CALR 突变负担与原发性血小板增多症的疾病结局。
Blood. 2024 Mar 28;143(13):1310-1314. doi: 10.1182/blood.2023023428.
4
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.骨髓纤维化异基因造血干细胞移植的适应证和处理：EBMT/ELN 国际工作组的更新建议。
Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4.
5
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.骨髓纤维化患者中CALR突变变异等位基因频率的表型相关性
Blood Cancer J. 2023 Jan 30;13(1):21. doi: 10.1038/s41408-023-00786-x.
6
Molecular prognostication in Ph-negative MPNs in 2022.2022 年 Ph 阴性 MPN 中的分子预后。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):225-234. doi: 10.1182/hematology.2022000339.
7
Myelofibrosis.骨髓纤维化。
Blood. 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423.
8
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
9
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.JAK2V617F 等位基因变异频率>50%可识别出患有静脉血栓形成高风险的真性红细胞增多症患者。
Blood Cancer J. 2021 Dec 11;11(12):199. doi: 10.1038/s41408-021-00581-6.
10
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.经典费城阴性骨髓增殖性肿瘤（MPNs）：一系列不同的疾病实体。
Int Rev Cell Mol Biol. 2021;365:1-69. doi: 10.1016/bs.ircmb.2021.09.001. Epub 2021 Sep 28.
Zotero 插件